The cell-line-derived subcutaneous tumor model in preclinical cancer research

Nat Protoc. 2022 Sep;17(9):2108-2128. doi: 10.1038/s41596-022-00709-3. Epub 2022 Jul 20.

Abstract

Tumor-bearing experimental animals are essential for preclinical cancer drug development. A broad range of tumor models is available, with the simplest and most widely used involving a tumor of mouse or human origin growing beneath the skin of a mouse: the subcutaneous tumor model. Here, we outline the different types of in vivo tumor model, including some of their advantages and disadvantages and how they fit into the drug-development process. We then describe in more detail the subcutaneous tumor model and key steps needed to establish it in the laboratory, namely: choosing the mouse strain and tumor cells; cell culture, preparation and injection of tumor cells; determining tumor volume; mouse welfare; and an appropriate experimental end point. The protocol leads to subcutaneous tumor growth usually within 1-3 weeks of cell injection and is suitable for those with experience in tissue culture and mouse experimentation.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Disease Models, Animal
  • Humans
  • Mice
  • Neoplasms*